Nonvenereal Syphilis Treatment Market Trends

  • Report ID: 3569
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Nonvenereal Syphilis Treatment Market Trends

Growth Drivers

  • Rising Prevalence of Infectious Diseases – diseases such as syphilis, bejel, pinta, and yaws are rare but it’s increasing prevalence worldwide is leading to surging investments in its prevention & treatment which is expected to boost the growth of the nonvenereal syphilis treatment market in the projected years. Centers for Disease Control and Prevention unveiled that in 2019 around 129,813 cases of all stages of syphilis, were reported worldwide.
  • Growing Burden of Incidences Associated with Bacterial Pathogens – as per a study nearly 7·7 million deaths globally were associated with 33 different bacterial pathogens (both resistant and susceptible to antimicrobials), which comprised nearly 13·6% of all global deaths and 56·2% of all sepsis-related deaths in 2019. Owing to these widespread concerns about bacterial pathogens, the government of various countries is joining hands to eradicate diseases caused by different pathogens, which will indirectly result in improved rapid diagnostic tests to detect syphilis and nonvenereal syphilis and its treatment.
  • Rising Cases of Diseases Caused by Treponema species – diseases such as yaws are gaining prevalence, mostly in children. It is observed that nearly 75–80% of people affected by yaws are children under 15 years of age with peak incidences occurring in children aged 6–10 years. Hence, this has elevated research on medications and treatment of diseases caused by Treponema species that also cause bejel, and pinta and is morphologically and serologically indistinguishable from the agent syphilis This, as a result, is expected to propel the market growth in the projected years.
  • Strategies to Eradicate Neglected Tropical Diseases – World Health Organization (WHO) has drawn a 2021-2030 roadmap for the eradication of rare tropical diseases which include syphilis, yaws, and bejel to attain the Sustainable Development Goals. The roadmap was prepared through an extensive global consultation pursuant to decision EB146(9) of the Executive Board at WHO’s 146th session in February 2020.

Challenges

  • Persistent Challenges in the Diagnostic Landscape and Testing Models – are hindering global nonvenereal syphilis control efforts. The challenges in the diagnosis of active syphilis infection, bejel, yaws, and pinta diseases owing to insufficient research and development in key areas and the present technological, individual, and structural barriers in access to nonvenereal syphilis testing is a major restraining factor of nonvenereal syphilis treatment market.
  • Lack of Highly Trained Laboratory Technologists and Complex/ Expensive Laboratory Instruments
  • Lack of Healthcare Infrastructure

Nonvenereal Syphilis Treatment Market: Key Insights

Healthcare Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Base Year

2024

Forecast Year

2025-2037

CAGR

8.90%

Base Year Market Size (2024)

USD 332.06 million

Forecast Year Market Size (2037)

USD 1.01 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)

Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3569
  • Published Date: Dec 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of nonvenereal syphilis treatment is estimated at USD 381.03 million.

The nonvenereal syphilis treatment market size was over USD 332.06 million in 2024 and is anticipated to cross USD 1.01 billion by 2037, growing at more than 8.9% CAGR during the forecast period i.e., between 2025-2037. The rising cases of bejel as well as the increasing augmentation of infectious diseases will drive the market growth.

Middle East and Africa industry is likely to hold largest revenue share by 2037, attributed to existence of nonvenereal syphilis in regions of West Africa, the Mediterranean, and the Sahara propelled by lack of sanitization as well as the hot and humid climate.

The major players in the market are Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample